HealthBeacon PLC HealthBeacon - HBCN - Integrated Smart Scale launch

Healthbeacon

15/07/2022 14:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220715:nRSO6929Sa&default-theme=true

RNS Number : 6929S  HealthBeacon PLC  15 July 2022

HealthBeacon launches its integrated Smart Scale

 

Dublin, 15 July 2022: Healthbeacon plc, the leading digital therapeutics
company that develops products for managing injectable medications for
patients in the home, has today announced the launch of its new Smart Scale,
an integrated solution that forms part of its Injection Care Management System
(ICMS).

 

The HealthBeacon Smart Scale enables patients to add weight monitoring to its
ICMS, as the connected weight scale tracks weight progression, providing
clinical teams with insights on specific medication outcomes.

 

There are currently nine million patients in the U.S. that self-administer
injectable medications in the home, and many require their weight to be
carefully managed and monitored. HealthBeacon's integrated Smart Scale will
sync seamlessly with its ICMS, helping patients improve adherence to therapies
and providing healthcare practitioners with access to important clinical
data.

 

HealthBeacon provides each member of its injection care management system with
a Smart Sharps Bin, a companion app, a more sustainable waste management
service, and now, the integrated Smart Scale. This enhances a system that
already improves the likelihood of success on therapy by increasing adherence
by as much as 26% and persistence by 19% according to peer reviewed research.

 

It is expected that the HealthBeacon Smart Scale will become available to
HealthBeacon patients this autumn.

 

Commenting, HealthBeacon CEO and co-founder, Jim Joyce, said: "The launch of
the HB Smart Scale is an important step as we strive to improve injection
adherence globally. Weight management is an important factor in the health of
many patients that are required to self-administer injectable medications at
home. This product integrates seamlessly into our technology which patients
are already using, meaning this addition can improve their health with no
added level of complexity."

 

The announcement of the launch of HealthBeacon's Smart Scale was made at the
annual MAGIC conference in Chicago, the largest patient conference for
children with growth disorders. The monitoring of weight progression is of
particular importance to children suffering from growth disorders.

 

Commenting further, Mr Joyce said: "We know how difficult it is for families
that must administer injections to their children at home. For children on
growth hormones, it can be difficult to both manage injections and monitor
growth progress. HealthBeacon's Smart Scale will support affected families by
enabling parents to track their child's growth along with monitoring injection
adherence. It also benefits children as they become teenagers and can
administer medication themselves, providing them with a level of independence
while enabling their parents to continue to monitor their adherence and track
their growth."

 Enquiries:
 HealthBeacon:                                    Investor.Relations@HealthBeacon.com

                                                (mailto:Investor.Relations@HealthBeacon.com)
 Laurence Flavin

 Goodbody (Euronext Listing Sponsor and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Billy Murphy                                     +353 (0) 87 231 3085
 Cathal Barry                                     +353 (0) 87 227 9281

 

Ends

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops products for managing injectable medications for patients in the
home. The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics. The
Company operates across Europe, North America and the United Kingdom and
employs more than 70 people and has obtained more than 30 design and utility
patents. Peer reviewed evidence supports a 19% improvement in therapy
persistence by patients and up to 26% improvement in adherence to therapy,
which improves clinical outcomes and significantly improves efficiency in
health systems. The Company's mission is to become the world's leading digital
therapeutics platform for injectable medications.

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISELELFFLDLEBBK